Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Switzerland

European Research Council grant · Running

REMIND Resolving CNS-to-Monocyte crosstalk In NeuroInflammatory Disease

Coordinator
Universitat Zurich, Switzerland
Runs
1 January 2027 to 31 December 2031
Status
Running
EU funding
€2.0m
Total cost
€2.0m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101302467

What the project is doing

In the project's own words, from its summary on CORDIS.

The central nervous system (CNS) is tightly connected to the immune system, with border regions such as the meninges and choroid plexus acting as key immunosurveillance hubs. Dysregulation of the immune cell landscape can drive neuropathology, including neuroinflammation and cancer. Growing evidence highlights monocyte-derived cells (MdCs) as critical players, yet their functions and mechanisms remain poorly understood.

Identifying and studying MdCs has been difficult because they closely resemble tissue-resident phagocytes, including microglia. Emerging single-cell atlases offer resolution but remain largely descriptive, mapping diversity without explaining how MdC states arise, when they change, or what they do. Our work shows that MdCs can be both tissue-damaging and protective in neuroinflammation. This functional dichotomy appears context-dependent, shaped by the local microenvironment, consistent with compartmentalized inflammation in progressive multiple sclerosis (MS).

To move beyond correlation and determine how CNS niches dictate MdC function, I propose REMIND, an integrated three-step research plan that combines spatiotemporal transcriptomic profiling to define context-dependent molecular and metabolic MdC programs (Aim 1: Discovery) with flow cytometry to link trajectories to functions at the protein level and conditional gene targeting to establish causal mechanisms and disease impact (Aim 2: Mechanism).

Aligning the findings with human disease will advance the development of biomarker and therapeutic strategies for progressive MS, a major unmet medical need (Aim 3: Translation). Together, REMIND will reframe how MdCs are viewed—moving beyond static “good vs. bad” labels to a dynamic, context-dependent causal model of imprinting that can be redirected. By clarifying how CNS niches shape MdC fate and function, this provides the mechanistic basis for improved diagnosis, progression monitoring, and targeted interventions in patients with CNS disorders.

Topics

Who is involved

OrganisationCityCountryRole
Universitat ZurichZurichSwitzerlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI